Labcorp, a global life sciences company, is collaborating with Xcell Biosciences (Xcellbio), a developer of cell and gene therapy technologies, to advance work that helps clients effectively bring innovative cell and gene therapies to market.
Through their collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). This strengthens Labcorp’s commitment to growing its global, comprehensive suite of CGT capabilities, and it supports pharmaceutical and biotechnology companies’ efforts to expedite therapeutic development.
“Labcorp is firmly committed to helping our clients bring new treatment options to patients in need while revolutionizing the future of medicine with cell and gene therapies,” said Dr. Maryland Franklin, vice president and enterprise head of cell and gene therapy at Labcorp.
“By pairing the scale and breadth of our enterprise-wide CGT solutions with Xcellbio’s powerful technology, we have an opportunity to enhance and accelerate the CGT development experience. It’s another way Labcorp is carrying out its mission to improve health and improve lives.”
CGTs modify a person’s genes to treat disease by inactivating or replacing a disease-causing gene, or introducing a new or modified cell or gene. CGTs are being tested for use in the treatment of many diseases, including Parkinson’s disease, an array of rare diseases, and both solid tumors and blood-based cancers.
The projects included in the collaboration will use Xcellbio’s AVATAR incubator system to grow and expand research-grade CAR-T cell material used to attack cancer cells. This work helps demonstrate the power of understanding the parameters of the tumor microenvironment in the creation of CAR-T cells with improved performance. In addition, the technology will be used to acclimate cancer cells to more physiologic conditions and expand 3D modeling for in vitro CAR-T testing.
“We’re continuously striving to advance cell and gene therapy development through technology innovations that enable the precise control of cell populations to enhance the potency and persistence needed for optimal patient outcomes,” said Brian Feth, CEO of Xcellbio.
“The exciting projects we’re undertaking with Labcorp allow our shared clients to harness the institutional knowledge and resources of a global organization to craft innovative approaches to develop potentially curative treatments.”
The collaboration—the latest in Labcorp’s string of recent CGT-focused relationships—follows the company’s strategic investment in Xcellbio in November 2021.